Argentina’s IVERCAR Ivermectin & Carrageenan Study Shows Positive Results Targeting COVID-19
Based in the southern end of Greater Buenos Aires, Argentina, Eurnekian Public Hospital recently sponsored a clinical trial targeting COVID-19 called the IVERCAR study.
The sponsor was joined by other local hospitals acting as trial site organizations.With study results in,
the Argentinian group has discovered
that while in the control group, 58% of the participants were infected with COVID-19 during the trial,but the intervention arm (carrageenan plus ivermectin) revealed
that the compound’s virucidal effects can actually protect patients against SARS-CoV-2 and serve as a sort of prophylaxis.These study results
follow up on other positive results out of another randomized controlled study out of Egypt published by TrialSite last week.
Intervention CombinationThis study used a combination of ivermectin (Ivercass) and iota Carrageenan.
The hypothesis involving iota carrageenan comes out of a recently published study in preprint server bioRxiv found
that the compound typically used as a thickening agent in food products successfully inhibited SARS-CoV-2 in cell cultures at a concentration as low as 6ug/ml.